Basiliximab as Induction in Kidney Transplantation: Are There any Real-Life Advantages?

Abstract

Background: Basiliximab is an interleukin-2 receptor antagonist used as induction therapy in kidney transplantation and is believed to reduce acute rejection episode (ARE). Our aims were to compare the impact of basiliximab induction therapy with no induction therapy on incidence of ARE, time requirement for serum creatinine (S.Cr) to normalize after transplantation, initial post-transplant hospital stay, infection in immediatepost-transplant period, chronic allograft injury and graft survival at 1 and 3 years.